NCT04425382View on ClinicalTrials.gov

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

July 31, 2020

Study Completion Date

September 30, 2020

Conditions
CoronavirusCOVIDPneumonia
Interventions
DRUG

Darunavir/Cobicistat

Darunavir/Cobicistat (800mg/150mg) 1 tablet PO once daily

DRUG

Lopinavir/Ritonavir

Lopinavir/Ritonavir (200mg/50mg) 2 tablets PO twice daily

Trial Locations (1)

Unknown

Hamad Medical Corporation, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY